Recon: Merck’s endometrial cancer treatment falters in study; Novo signs $600M deal with Metaphore to develop new obesity drugs

• Lawmakers consider limiting how long existing WuXi contracts can continue (Endpoints)
• Merck's endometrial cancer therapy fails trial (Reuters)
• Beyond CAR-Ts: Cell-Based Gene Therapy Sponsors Are ‘Branching Out,’ CBER’s Marks Says (Pink Sheet)
• Drug supplies for millions would be jeopardized by U.S. crackdown on China biopharma industry, trade group says (STAT)
• US FDA advises healthcare facilities to switch from Getinge's heart devices (Reuters)

• Novo Nordisk ties up with Metaphore to develop new obesity drugs (Reuters) (Endpoints)
• A new cholera vaccine will increase supply, but will it be enough to manage global outbreaks? (STAT)
• Japan's Takeda Pharma to restructure after annual profit slump (Reuters)
• Drugmaker Abbott India posts Q4 profit rise on higher sales (Reuters)
• UK refuses to sign global vaccine treaty, The Telegraph reports (Reuters)
• AstraZeneca to withdraw COVID vaccine globally as demand dips (Reuters)
• ‘Don’t Cut Corners’ If You Want To Succeed, EMA Orphan Drug Head Tells Sponsors (Pink Sheet)

• Cytokinetics set to pitch its heart drug to physicians — and Big Pharma suitors (STAT)
• Yet another big financing round in immunology (STAT)
• After gene therapy, two congenitally deaf children hear for the first time (STAT)
• Acelyrin's founding CEO steps down, company scraps earnings call (Endpoints)
• Infectious disease biotech Bluejay raises $182M for hepatitis trials (Endpoints)
• Freeline unveils early efficacy signal for Gaucher gene therapy: #ASGCT24 (Endpoints)
• Takeda to revamp in multiyear quest, pivots CAR-NK therapy from cancer to autoimmune (Endpoints)
• Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates (Reuters)
• CytomX shares plummet as Amgen-partnered cancer drug yields jumbled Phase 1 data (Endpoints)
• Attovia reels in $105M from crossover investors to run multiple trials of I&I biologics (Endpoints)
• Aardvark nabs $85M to target hunger, not appetite, as it eyes 2026 NDA filing (Endpoints)
• Danish biotech nabs Novo Holdings support in seed round for complement platform (Endpoints)
• Viagra maker Viatris misses revenue estimates on weak demand for older drugs (Reuters)
• US FDA Transparency Win: Sponsors Know More Product-Specific Guidances Coming, Requests Fall (Pink Sheet) 
• Accelerated Approval: Withdrawing Gene Therapies Could Be Easier Than Small Molecules (Pink Sheet)

• Tandem reports 224 injuries related to faulty insulin pump app (MedTech Dive)
• Samsung Medison to buy AI ultrasound company Sonio (MedTech Dive)
• Geneoscopy wins FDA approval for Labcorp-partnered colon cancer test (MedTech Dive)
• Integra still addressing problems at Boston plant (MedTech Dive)

• As livestock move around the country, so does H5N1. The U.S. needs real-time tracking of livestock movements (STAT)
• H5N1 communication has been strictly for the birds. Didn’t the federal government learn anything from Covid? (STAT)